Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-Results of the randomized EORTC Phase III trial 22961

被引：0
|
作者：
Bolla, M.
van Tienhoven, G.
de Reijke, T. M.
van den Bergh, A. C.
van der Meijden, A. P.
Poortmans, P. M.
Gez, E.
Kil, P.
Pierart, M.
Collette, L.
机构：
[1] Ctr Hosp Reg Grenoble, Grenoble, France
[2] Acad Med Ctr, Amsterdam, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Jeroen Bosch Ziekenhuis, Shertogenbosch, Netherlands
[5] Doctor Bernard Verbeeten Inst, Tilburg, Netherlands
[6] Rambam Med Ctr, Haifa, Israel
[7] Sint Elisabethziekenhuis, Tilburg, Netherlands
[8] EORTC Data Ctr, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5014
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Six months versus three years concomitant and adjuvant hormonal treatment with external beam irradiation for locally advanced prostate cancer: Results of the EORTC randomized Phase III trial 22961
    Bolla, M.
    Van Tienhoven, G.
    De Reijke, T. H. M.
    Van den Bergh, F.
    Oddens, J. O. R. G.
    Poortmans, P.
    Gez, E.
    Kil, P.
    Musat, E.
    Collette, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 279 - 279
  • [2] Six-month concomitant and adjuvant hormonal treatment with external beam irradiation is inferior to 3-years hormonal treatment for locally advanced prostate cancer: Results of the eortc randomised phase III trial 22961
    Bolla, M.
    De Reijke, Th. M.
    Van Tienhoven, G. J.
    Van Den Bergh, A. C. M.
    Oddens, J.
    Poortmans, P. M. P.
    Gez, E.
    Kil, P. J. M.
    Musat, E.
    Collette, L.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 117 - 117
  • [3] Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer
    Mottet, N.
    Peneau, M.
    Mazeron, J.
    Molinie, V.
    Richaud, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Results of a Phase III Trial of Optimal Sequencing of Dose Escalated Radiation (XRT) and 6 Months Androgen Deprivation Therapy (ADT) in Prostate Cancer
    Malone, S.
    Eapen, L.
    Kendal, W. S.
    MacRae, R. M.
    Perry, G.
    Malone, K.
    Bowen, J.
    Craig, J.
    Grimes, S.
    Morgan, S. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S33 - S33
  • [5] Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: Results at 10 years of EORTC trial 22863
    Bolla, M.
    Collette, L.
    Van Tienhoven, G.
    Warde, P.
    Dubois, J. B.
    Mirimanoff, R. O.
    Storme, G. A.
    Bernier, J.
    Kuten, A.
    Pierart, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 408 - 408
  • [6] A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).
    Haresh, K. P.
    Vjaters, Egils
    Castellano, Daniel
    Olmos, David
    Shore, Neal D.
    Nevalaita, Liina
    Testa, Isabella
    Kappeler, Christian
    Kuss, Iris
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [7] Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    Bolla, M
    Collette, L
    Blank, L
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Mattelaer, J
    Torecilla, JL
    Pfeffer, JR
    Cutajar, CL
    Zurlo, A
    Pierart, M
    LANCET, 2002, 360 (9327): : 103 - 108
  • [8] External irradiation combined with androgen suppression in patients with locally advanced prostate cancer: long term better than short term. Results of an EORTC phase III randomized trial
    Bolla, M.
    Collette, L.
    De Reijke, T. H. M.
    BULLETIN DU CANCER, 2008, 95 : S76 - S76
  • [9] SURVIVAL ANALYSIS OF A RANDOMIZED PHASE III TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL VERSUS ADT ALONE IN HORMONE-SENSITIVE METASTATIC PROSTATE CANCER (GETUG-AFU 15/0403)
    Gravis, G.
    Fizazi, K.
    Lobbedez, F. Joly
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Krakowski, I.
    Laguerre, B.
    Rolland, F.
    Theodore, C.
    Deplanque, G.
    Ferrero, J. M.
    Pouessel, D.
    Mourey, L.
    Beuzeboc, P.
    Zanetta, S.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 294 - 294
  • [10] IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)-RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS) IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)-RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS)
    Cussenot, Olivier
    Penna, Raphaele Renard
    Comperat, Eva
    Azzouzi, Abdel-Rahmene
    Costa, Pierre
    Larre, Stephane
    Ruffion, Alain
    Fasla, Ludmila
    Delavierre, Dominque
    Rebillard, Xavier
    Pfister, Christian
    Fendler, Jean-Philippe
    Vesga, Jorgea Villamizar
    Staerman, Frederic
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1076 - E1077
12345